Literature DB >> 21460829

Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia.

Wei Xiong1, Kejun Cheng, Tanxing Cui, Grzegorz Godlewski, Kenner C Rice, Yan Xu, Li Zhang.   

Abstract

Cannabinoids enhance the function of glycine receptors (GlyRs). However, little is known about the mechanisms and behavioral implication of cannabinoid-GlyR interaction. Using mutagenesis and NMR analysis, we have identified a serine at 296 in the GlyR protein critical for the potentiation of I(Gly) by Δ(9)-tetrahydrocannabinol (THC), a major psychoactive component of marijuana. The polarity of the amino acid residue at 296 and the hydroxyl groups of THC are critical for THC potentiation. Removal of the hydroxyl groups of THC results in a compound that does not affect I(Gly) when applied alone but selectively antagonizes cannabinoid-induced potentiating effect on I(Gly) and analgesic effect in a tail-flick test in mice. The cannabinoid-induced analgesia is absent in mice lacking α3GlyRs but not in those lacking CB1 and CB2 receptors. These findings reveal a new mechanism underlying cannabinoid potentiation of GlyRs, which could contribute to some of the cannabis-induced analgesic and therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460829      PMCID: PMC3388539          DOI: 10.1038/nchembio.552

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  44 in total

Review 1.  Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses?

Authors:  Bodo Laube; Gábor Maksay; Rudolf Schemm; Heinrich Betz
Journal:  Trends Pharmacol Sci       Date:  2002-11       Impact factor: 14.819

2.  Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.

Authors:  N E Buckley; K L McCoy; E Mezey; T Bonner; A Zimmer; C C Felder; M Glass; A Zimmer
Journal:  Eur J Pharmacol       Date:  2000-05-19       Impact factor: 4.432

3.  Afferent and efferent connections of the rat tail flick reflex (a model used to analyze pain control mechanisms).

Authors:  M L Grossman; A I Basbaum; H L Fields
Journal:  J Comp Neurol       Date:  1982-03-20       Impact factor: 3.215

Review 4.  Therapeutic potential of cannabinoid-based drugs.

Authors:  Thomas W Klein; Catherine A Newton
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

5.  Arginine 222 in the pre-transmembrane domain 1 of 5-HT3A receptors links agonist binding to channel gating.

Authors:  Xiang-Qun Hu; Li Zhang; Randall R Stewart; Forrest F Weight
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

6.  GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization.

Authors:  Robert J Harvey; Ulrike B Depner; Heinz Wässle; Seifollah Ahmadi; Cornelia Heindl; Heiko Reinold; Trevor G Smart; Kirsten Harvey; Burkhard Schütz; Osama M Abo-Salem; Andreas Zimmer; Pierrick Poisbeau; Hans Welzl; David P Wolfer; Heinrich Betz; Hanns Ulrich Zeilhofer; Ulrike Müller
Journal:  Science       Date:  2004-05-07       Impact factor: 47.728

7.  Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia.

Authors:  P B Smith; B R Martin
Journal:  Brain Res       Date:  1992-04-24       Impact factor: 3.252

8.  Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1.

Authors:  Sven-Eric Jordt; Diana M Bautista; Huai-Hu Chuang; David D McKemy; Peter M Zygmunt; Edward D Högestätt; Ian D Meng; David Julius
Journal:  Nature       Date:  2004-01-07       Impact factor: 49.962

9.  NMR structures of the second transmembrane domain of the human glycine receptor alpha(1) subunit: model of pore architecture and channel gating.

Authors:  Pei Tang; Pravat K Mandal; Yan Xu
Journal:  Biophys J       Date:  2002-07       Impact factor: 4.033

10.  Glycine receptor knock-in mice and hyperekplexia-like phenotypes: comparisons with the null mutant.

Authors:  Geoffrey S Findlay; Rachel Phelan; Michael T Roberts; Gregg E Homanics; Susan E Bergeson; Gregory F Lopreato; S John Mihic; Yuri A Blednov; R Adron Harris
Journal:  J Neurosci       Date:  2003-09-03       Impact factor: 6.167

View more
  49 in total

1.  Atomistic insights into human Cys-loop receptors by solution NMR.

Authors:  David D Mowrey; Monica N Kinde; Yan Xu; Pei Tang
Journal:  Biochim Biophys Acta       Date:  2014-03-28

2.  Open-channel structures of the human glycine receptor α1 full-length transmembrane domain.

Authors:  David D Mowrey; Tanxing Cui; Yuanyuan Jia; Dejian Ma; Alexander M Makhov; Peijun Zhang; Pei Tang; Yan Xu
Journal:  Structure       Date:  2013-08-29       Impact factor: 5.006

3.  Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia disease.

Authors:  Wei Xiong; Shao-Rui Chen; Liming He; Kejun Cheng; Yi-Lin Zhao; Hong Chen; De-Pei Li; Gregg E Homanics; John Peever; Kenner C Rice; Ling-gang Wu; Hui-Lin Pan; Li Zhang
Journal:  Nat Neurosci       Date:  2014-01-05       Impact factor: 24.884

Review 4.  Allosteric modulation of glycine receptors.

Authors:  Gonzalo E Yevenes; Hanns Ulrich Zeilhofer
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  Receptors: cannabis medicine without a high.

Authors:  Macdonald J Christie; Christopher W Vaughan
Journal:  Nat Chem Biol       Date:  2011-05       Impact factor: 15.040

6.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Glycine receptors and glycine transporters: targets for novel analgesics?

Authors:  Hanns Ulrich Zeilhofer; Mario A Acuña; Jacinthe Gingras; Gonzalo E Yévenes
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

Review 8.  Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

Authors:  John M McPartland; Marnie Duncan; Vincenzo Di Marzo; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-02       Impact factor: 8.739

Review 9.  Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

Authors:  Henry L Blanton; Jennifer Brelsfoard; Nathan DeTurk; Kevin Pruitt; Madhusudhanan Narasimhan; Daniel J Morgan; Josée Guindon
Journal:  Drugs       Date:  2019-06       Impact factor: 9.546

Review 10.  Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system.

Authors:  Alexander F Hoffman; Carl R Lupica
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.